Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John H Laragh

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Clinical Cardiology|March 8, 2003
Hypertension is not all alike nor are its treatments: where would a better calcium-channel blocker fit in a modern treatment system?John H Laragh
American Journal of Hypertension|December 13, 2006
Dr. Michael H. Alderman takes the helm as editor-in-chief of the American Journal of HypertensionJohn H Laragh
Hypertension (Dallas, Tex. : 1979)|July 9, 2008
It is the plasma renin activity level that counts, not stoichiometryJean E Sealey, John H Laragh
American Journal of Hypertension|May 15, 2003
Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHATJohn H Laragh, Jean E Sealey
American Journal of Hypertension|September 20, 2008
Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively risesJean E Sealey, John H Laragh
Clinical Chemistry|December 15, 2010
Plasma renin activity enzyme-kinetic assay: protection of Angiotensin I from bacterial degradationJean E Sealey, John H Laragh
American Journal of Hypertension|August 25, 2009
Using plasma renin (PRA) testing to design follow-up drug treatment strategies in hypertensive patients already taking antirenin system drugsJean E Sealey, John H Laragh
BMJ (Clinical Research Ed.)|March 21, 2013
Sodium depletion in patients in clinical trials may account for the increased cardiovascular risk of dual blockade of the renin-angiotensin systemJohn H Laragh, Jean E Sealey
American Journal of Hypertension|May 9, 2007
Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectivenessJean E Sealey, John H Laragh
BMJ (Clinical Research Ed.)|April 18, 2013
Authors' reply to Messerli and colleaguesJohn H Laragh, Jean E Sealey
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Clinical Cardiology|March 8, 2003
Hypertension is not all alike nor are its treatments: where would a better calcium-channel blocker fit in a modern treatment system?John H Laragh
American Journal of Hypertension|December 13, 2006
Dr. Michael H. Alderman takes the helm as editor-in-chief of the American Journal of HypertensionJohn H Laragh
Hypertension (Dallas, Tex. : 1979)|July 9, 2008
It is the plasma renin activity level that counts, not stoichiometryJean E Sealey, John H Laragh
American Journal of Hypertension|May 15, 2003
Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHATJohn H Laragh, Jean E Sealey
American Journal of Hypertension|September 20, 2008
Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively risesJean E Sealey, John H Laragh
Clinical Chemistry|December 15, 2010
Plasma renin activity enzyme-kinetic assay: protection of Angiotensin I from bacterial degradationJean E Sealey, John H Laragh
American Journal of Hypertension|August 25, 2009
Using plasma renin (PRA) testing to design follow-up drug treatment strategies in hypertensive patients already taking antirenin system drugsJean E Sealey, John H Laragh
BMJ (Clinical Research Ed.)|March 21, 2013
Sodium depletion in patients in clinical trials may account for the increased cardiovascular risk of dual blockade of the renin-angiotensin systemJohn H Laragh, Jean E Sealey
American Journal of Hypertension|May 9, 2007
Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectivenessJean E Sealey, John H Laragh
BMJ (Clinical Research Ed.)|April 18, 2013
Authors' reply to Messerli and colleaguesJohn H Laragh, Jean E Sealey
Pageof 4